Dr. MiltieAtlas by Dr. Miltie™Healthcare Grant Intelligence
Active — deadline conflict; confirm live eMMA cutoffAtlas Opportunity Score 92/100

Maryland Young Adult Sickle Cell Care Transition Program — PHPA 4078 / BPM058515

Maryland Department of Health is seeking one grantee to develop or strengthen a comprehensive transition program for young adults with sickle cell disease moving from pediatric to adult-centered care. The RFA requires transition coordination, psychosocial assessment, referral systems, evidence-informed readiness tools, workflows, staffing and quarterly outcome reporting. Atlas uses September 15, 2026 at 12:00 PM ET as a conservative operational cutoff because the available procurement materials contain conflicting close-date displays; applicants should confirm the live BPM058515 deadline in eMMA before submission.

FundingOne anticipated cost-reimbursable award. The RFA reviewed by Atlas does not publish a fixed grant ceiling; applicants propose a justified project budget and Atlas does not invent an amount.
DeadlineConservative operational cutoff: September 15, 2026 at 12:00 PM ET unless the live eMMA record establishes a later controlling time. The RFA itself contains conflicting dates: the Key Information Summary Sheet states September 16, 2026 at 2:00 PM local time, while Section 1.7 states September 15, 2026 at 2:00 PM local time. Questions are requested by September 9, 2026.
Last verifiedSeptember 6, 2026
Required next actionImmediately search BPM058515 in eMaryland Marketplace Advantage and confirm the live closing date/time and all addenda. Eligible applicants should complete the project narrative, work plan and separate budget narrative; document nonprofit/government/public-college eligibility and Maryland good standing; designate transition-program staffing including a Transition Coordinator; define referral and care-continuity workflows; and submit before September 15 at noon ET unless eMMA clearly establishes a different controlling cutoff.

Broad Eligibility

Eligible pathways include qualifying social organizations, local or state government agencies, public colleges and state universities. Social-organization applicants must be nonprofit 501(c)(3) organizations and provide tax-exempt documentation. The applicant must satisfy eMMA registration, Maryland good-standing and all mandatory RFA submission requirements.

Atlas Analysis

Atlas Opportunity Score 92/100. Strong Maryland specialty-care and pediatric-to-adult transition opportunity requiring comprehensive sickle-cell transition planning, a skilled Transition Coordinator, psychosocial assessment, medical-legal navigation, crisis intervention, evidence-informed readiness tools, referral coordination, health-literacy and self-management support, and measurable continuity-of-care outcomes. N9+ Direct Vendor Fit 8/100 because the verified scope does not establish connected-exam, telehealth-equipment or RPM procurement. QC Healthcare Fit 18/100 conditional because clinical coordination is central but stand-alone physician coverage is not the procurement purpose. Deadline-control warning: the RFA Key Sheet and Section 1.7 conflict, so applicants must verify BPM058515 in live eMMA before relying on a later date.

Maryland Sickle Cell Transition-Care Funding

The Maryland Department of Health (MDH), Office of Children and Youth with Specific Health Care Needs, issued competitive RFA PHPA 4078 / BPM058515 to support young adults with sickle cell disease as they move from pediatric to adult-centered care. MDH intends to make one award. The agreement is cost-reimbursable, with an anticipated initial service period from October 1, 2026 through June 30, 2027 and two potential one-year options through June 30, 2029.

Deadline Control — Confirm eMMA

The solicitation materials contain a material deadline conflict. The RFA Key Information Summary Sheet displays a closing date of September 16, 2026 at 2:00 PM local time, while RFA Section 1.7 states applications must be received in eMaryland Marketplace Advantage (eMMA) no later than September 15, 2026 at 2:00 PM local time. A current procurement index mirror displays September 15 at noon. Atlas therefore uses September 15, 2026 at 12:00 PM ET as the conservative operational submission target unless the live eMMA record for BPM058515 clearly establishes a later controlling cutoff. Questions are requested by September 9, 2026.

Who Can Apply

The RFA permits a qualifying social organization, local or state government agency, public college or state university. A social-organization applicant must be a nonprofit organization recognized by the IRS under section 501(c)(3) and provide the required tax-exempt documentation. Applicants must be registered in eMMA to receive an award and must satisfy Maryland good-standing and other mandatory submission requirements.

What the Program Must Do

The funded program must develop or enhance a comprehensive transition model for adolescents and young adults with sickle cell disease. Required work includes strengthening patient-parent-provider relationships; integrating a Transition Coordinator capable of psychosocial assessment, navigation of complex medical-legal systems and crisis intervention; using evidence-informed transition-readiness tools and action plans; creating administrative protocols and workflows; and coordinating referrals with primary care, mental-health professionals, MDH-funded community health workers and applicable Hub-and-Spoke programs.

The program must also address health literacy, developmental maturity, family functioning, self-management, neurocognitive considerations and provider-patient communication. Quarterly reporting includes referrals, participation, transition-readiness scores, transition plans, successful transfer to comprehensive adult sickle-cell care, continuity of care, integration into adult care, and patient/provider/parent satisfaction.

Budget and Award Structure

The RFA does not publish a fixed award ceiling in the solicitation text reviewed by Atlas. Applicants submit a detailed cost-reimbursable budget covering allowable project costs such as personnel, consultants, travel, contractual expenses, supplies, operating costs and other justified project-related costs. Atlas does not invent a dollar estimate where MDH has not published one.

Atlas Analysis

Atlas Opportunity Score: 92/100. This is a highly targeted pediatric-to-adult specialty-care transition opportunity with a clear clinical need, defined care-coordination model, measurable outcomes and a direct Maryland public-health sponsor. The narrow applicant pool, single-award structure, short capture window and unresolved deadline display reduce the score from the very highest tier.

N9+ Direct Vendor Fit: 8/100. The verified scope centers on transition coordination, psychosocial support, workflows, referral systems and continuity of specialty care. The RFA does not establish connected physical-exam hardware, telehealth equipment or remote-monitoring procurement as a core funded activity, so Atlas will not force a technology fit.

QC Healthcare Fit: 18/100 conditional. The program requires coordination with adult sickle-cell and other clinical providers, but it is not a stand-alone physician-coverage procurement. Any clinical subcontracting must be justified within the applicant-led transition model and the controlling RFA.

Next Action

Eligible Maryland organizations should search BPM058515 in eMaryland Marketplace Advantage, review every current addendum and Q&A, verify the live closing date/time, complete the project narrative and work plan, build the separate budget narrative, document nonprofit/government/education eligibility and good standing, and submit before Atlas’s conservative September 15 noon operational target unless eMMA clearly establishes a different controlling cutoff.

Official procurement system: eMaryland Marketplace Advantage (search BPM058515).

Source verificationOfficial government source · emma.maryland.govAtlas last verified this record September 6, 2026. Always use the funder's current application materials, amendments and portal instructions as the controlling source.View source and application materials ↗